Compare $DMAC vs $RZLT | Chartloom

Compare

$DMAC vs $RZLT

DiaMedica Therapeutics Inc · Rezolute Inc

DMAC

DiaMedica Therapeutics Inc

RZLT

Rezolute Inc

Compare $DMAC vs $RZLT

Comparing DiaMedica Therapeutics Inc and Rezolute Inc

DMACDiaMedica Therapeutics Inc

RZLTRezolute Inc

DMACDiaMedica Therapeutics Inc

Market cap

$449M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

5.0%

52W performance

19.7%

FCF yield

-7.0%

RZLTRezolute Inc

Market cap

$469M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

124.9%

52W performance

-44.2%

FCF yield

-13.8%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

DMAC

RZLT

Detailed metrics comparison

DMAC

DiaMedica Therapeutics Inc

RZLT

Rezolute Inc

Market Cap

DMAC$449M

RZLT$469M

Enterprise Value

DMAC$444M

RZLT$458M

Price

DMAC$8.33

RZLT$4.87

P/E Ratio

DMACN/A

RZLTN/A

P/S Ratio

DMAC0.00x

RZLT0.00x

EV/Sales

DMAC0.00x

RZLT0.00x

EV/EBITDA

DMAC0.00x

RZLT0.00x

P/B Ratio

DMAC11.58x

RZLT3.85x

P/FCF Ratio

DMACN/A

RZLTN/A

EV/FCF

DMAC-14.07x

RZLT-7.09x

PEG Ratio

DMACN/A

RZLTN/A

Forward P/E (NTM)

DMACN/A

RZLTN/A

Forward P/S (NTM)

DMACN/A

RZLTN/A

Revenue (TTM)

DMAC$0

RZLT$0

Revenue Growth (YoY)

DMACN/A

RZLTN/A

Forward Rev Growth

DMAC306.4%

RZLT2194.8%

Gross Margin (TTM)

DMAC0.0%

RZLT0.0%

Operating Margin (TTM)

DMAC0.0%

RZLT0.0%

EBITDA Margin (TTM)

DMAC0.0%

RZLT0.0%

Net Margin (TTM)

DMAC0.0%

RZLT0.0%

FCF Margin (TTM)

DMACN/A

RZLTN/A

Net Income (TTM)

DMAC$-38M

RZLT$-78M

FCF (TTM)

DMAC$-32M

RZLT$-65M

EPS (TTM)

DMAC-$0.70

RZLT-$0.74

ROE (TTM)

DMAC-7768.0%

RZLT-6299.0%

ROA (TTM)

DMAC-6936.0%

RZLT-5794.0%

ROIC (TTM)

DMAC-7766.0%

RZLT-6299.0%

Cash

DMAC$5M

RZLT$11M

Debt

DMAC$9K

RZLT$0

Net Cash/Debt

DMAC$5M

RZLT$11M

Current Ratio (TTM)

DMAC6.72x

RZLT9.68x

Quick Ratio (TTM)

DMAC6.63x

RZLT9.44x

Debt/Equity (TTM)

DMAC0.00x

RZLT0.00x

Debt/Assets (TTM)

DMAC0.0%

RZLT0.0%

Interest Coverage (TTM)

DMACN/A

RZLTN/A

Net Debt/EBITDA (TTM)

DMAC0.00x

RZLT0.00x

Beta

DMAC0.96

RZLT0.58

52W Performance

DMAC19.7%

RZLT-44.2%

YTD Performance

DMAC5.0%

RZLT124.9%

% from 52W High

DMAC-20.1%

RZLT-57.5%

% from 52W Low

DMAC58.8%

RZLT355.1%

Asset Turnover (TTM)

DMAC0.00x

RZLT0.00x

FCF Yield (TTM)

DMAC-7.0%

RZLT-13.8%

Earnings Yield (TTM)

DMAC-8.4%

RZLT-16.5%

Dividend Yield (TTM)

DMACN/A

RZLTN/A

Rule of 40

DMAC0.0

RZLT0.0

EV/GP/RG

DMACN/A

RZLTN/A

Ticker research

View DMAC research View RZLT research

Metric	DMAC DiaMedica Therapeutics Inc	RZLT Rezolute Inc
Market & Valuation
Market Cap	$449M	$469M
Enterprise Value	$444M	$458M
Price	$8.33	$4.87
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	11.58x	3.85x
P/FCF Ratio	N/A	N/A
EV/FCF	-14.07x	-7.09x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	306.4%	2194.8%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-38M	$-78M
FCF (TTM)	$-32M	$-65M
EPS (TTM)	-$0.70	-$0.74
ROE (TTM)	-7768.0%	-6299.0%
ROA (TTM)	-6936.0%	-5794.0%
ROIC (TTM)	-7766.0%	-6299.0%
Financial Health
Cash	$5M	$11M
Debt	$9K	$0
Net Cash/Debt	$5M	$11M
Current Ratio (TTM)	6.72x	9.68x
Quick Ratio (TTM)	6.63x	9.44x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.96	0.58
52W Performance	19.7%	-44.2%
YTD Performance	5.0%	124.9%
% from 52W High	-20.1%	-57.5%
% from 52W Low	58.8%	355.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-7.0%	-13.8%
Earnings Yield (TTM)	-8.4%	-16.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View DMAC research	View RZLT research

Valuation

P/S Ratio

DMAC

0.00x

RZLT

0.00x

EV/FCF

DMAC

-14.07x

RZLT

-7.09x

Growth & revenue

Forward Revenue Growth

RZLT

2194.8%

DMAC

306.4%

Profitability & performance

Gross Margin

DMAC

0.0%

RZLT

0.0%

ROE

RZLT

-6299.0%

DMAC

-7768.0%

FCF Yield %

DMAC

-7.0%

RZLT

-13.8%

52-Week Performance

DMAC

19.7%

RZLT

-44.2%

Detailed metrics comparison

DMAC

DiaMedica Therapeutics Inc

RZLT

Rezolute Inc

Market Cap

DMAC$449M

RZLT$469M

Enterprise Value

DMAC$444M

RZLT$458M

Price

DMAC$8.33

RZLT$4.87

P/E Ratio

DMACN/A

RZLTN/A

P/S Ratio

DMAC0.00x

RZLT0.00x

EV/Sales

DMAC0.00x

RZLT0.00x

EV/EBITDA

DMAC0.00x

RZLT0.00x

P/B Ratio

DMAC11.58x

RZLT3.85x

P/FCF Ratio

DMACN/A

RZLTN/A

EV/FCF

DMAC-14.07x

RZLT-7.09x

PEG Ratio

DMACN/A

RZLTN/A

Forward P/E (NTM)

DMACN/A

RZLTN/A

Forward P/S (NTM)

DMACN/A

RZLTN/A

Revenue (TTM)

DMAC$0

RZLT$0

Revenue Growth (YoY)

DMACN/A

RZLTN/A

Forward Rev Growth

DMAC306.4%

RZLT2194.8%

Gross Margin (TTM)

DMAC0.0%

RZLT0.0%

Operating Margin (TTM)

DMAC0.0%

RZLT0.0%

EBITDA Margin (TTM)

DMAC0.0%

RZLT0.0%

Net Margin (TTM)

DMAC0.0%

RZLT0.0%

FCF Margin (TTM)

DMACN/A

RZLTN/A

Net Income (TTM)

DMAC$-38M

RZLT$-78M

FCF (TTM)

DMAC$-32M

RZLT$-65M

EPS (TTM)

DMAC-$0.70

RZLT-$0.74

ROE (TTM)

DMAC-7768.0%

RZLT-6299.0%

ROA (TTM)

DMAC-6936.0%

RZLT-5794.0%

ROIC (TTM)

DMAC-7766.0%

RZLT-6299.0%

Cash

DMAC$5M

RZLT$11M

Debt

DMAC$9K

RZLT$0

Net Cash/Debt

DMAC$5M

RZLT$11M

Current Ratio (TTM)

DMAC6.72x

RZLT9.68x

Quick Ratio (TTM)

DMAC6.63x

RZLT9.44x

Debt/Equity (TTM)

DMAC0.00x

RZLT0.00x

Debt/Assets (TTM)

DMAC0.0%

RZLT0.0%

Interest Coverage (TTM)

DMACN/A

RZLTN/A

Net Debt/EBITDA (TTM)

DMAC0.00x

RZLT0.00x

Beta

DMAC0.96

RZLT0.58

52W Performance

DMAC19.7%

RZLT-44.2%

YTD Performance

DMAC5.0%

RZLT124.9%

% from 52W High

DMAC-20.1%

RZLT-57.5%

% from 52W Low

DMAC58.8%

RZLT355.1%

Asset Turnover (TTM)

DMAC0.00x

RZLT0.00x

FCF Yield (TTM)

DMAC-7.0%

RZLT-13.8%

Earnings Yield (TTM)

DMAC-8.4%

RZLT-16.5%

Dividend Yield (TTM)

DMACN/A

RZLTN/A

Rule of 40

DMAC0.0

RZLT0.0

EV/GP/RG

DMACN/A

RZLTN/A

Ticker research

View DMAC research View RZLT research

Metric	DMAC DiaMedica Therapeutics Inc	RZLT Rezolute Inc
Market & Valuation
Market Cap	$449M	$469M
Enterprise Value	$444M	$458M
Price	$8.33	$4.87
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	11.58x	3.85x
P/FCF Ratio	N/A	N/A
EV/FCF	-14.07x	-7.09x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	306.4%	2194.8%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-38M	$-78M
FCF (TTM)	$-32M	$-65M
EPS (TTM)	-$0.70	-$0.74
ROE (TTM)	-7768.0%	-6299.0%
ROA (TTM)	-6936.0%	-5794.0%
ROIC (TTM)	-7766.0%	-6299.0%
Financial Health
Cash	$5M	$11M
Debt	$9K	$0
Net Cash/Debt	$5M	$11M
Current Ratio (TTM)	6.72x	9.68x
Quick Ratio (TTM)	6.63x	9.44x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.96	0.58
52W Performance	19.7%	-44.2%
YTD Performance	5.0%	124.9%
% from 52W High	-20.1%	-57.5%
% from 52W Low	58.8%	355.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-7.0%	-13.8%
Earnings Yield (TTM)	-8.4%	-16.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View DMAC research	View RZLT research